AR041865A1 - Derivados terapeuticos de prolina y su uso en el tratamiento de epilepsia y dolor - Google Patents

Derivados terapeuticos de prolina y su uso en el tratamiento de epilepsia y dolor

Info

Publication number
AR041865A1
AR041865A1 ARP030103960A ARP030103960A AR041865A1 AR 041865 A1 AR041865 A1 AR 041865A1 AR P030103960 A ARP030103960 A AR P030103960A AR P030103960 A ARP030103960 A AR P030103960A AR 041865 A1 AR041865 A1 AR 041865A1
Authority
AR
Argentina
Prior art keywords
disorders
epilepsy
pain
treatment
prolina
Prior art date
Application number
ARP030103960A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR041865A1 publication Critical patent/AR041865A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de la fórmula (1) o una de sus sales, solvatos o profármacos farmacéuticamente aceptables, son derivados de prolina, útiles en el tratamiento de epilepsia, crisis de desmayos, hipoquinesia, trastornos craneales, trastornos neurodegenerativos, depresión, ansiedad, pánico, dolor, fibromialgia, artritis, trastornos neuropatológicos, trastornos del sueno, trastornos asociados con dolores gastrointestinales. Se incluyen procedimientos para la preparación de los productos finales y de intermediarios útiles en el procedimiento. también se incluyen composiciones farmacéuticas que contienen uno o más de los compuestos.
ARP030103960A 2002-10-31 2003-10-29 Derivados terapeuticos de prolina y su uso en el tratamiento de epilepsia y dolor AR041865A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0225379.7A GB0225379D0 (en) 2002-10-31 2002-10-31 Therapeutic proline derivatives

Publications (1)

Publication Number Publication Date
AR041865A1 true AR041865A1 (es) 2005-06-01

Family

ID=9946940

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103960A AR041865A1 (es) 2002-10-31 2003-10-29 Derivados terapeuticos de prolina y su uso en el tratamiento de epilepsia y dolor

Country Status (39)

Country Link
EP (1) EP1558246B1 (es)
JP (2) JP3940416B2 (es)
KR (2) KR100750782B1 (es)
CN (1) CN100418525C (es)
AP (1) AP2005003295A0 (es)
AR (1) AR041865A1 (es)
AT (1) ATE468116T1 (es)
AU (1) AU2003269411B2 (es)
BR (1) BR0315839A (es)
CA (1) CA2499698C (es)
CO (1) CO5550430A2 (es)
CR (1) CR7802A (es)
DE (1) DE60332646D1 (es)
DK (1) DK1558246T3 (es)
EA (1) EA009767B1 (es)
EC (1) ECSP055769A (es)
ES (1) ES2343624T3 (es)
GB (1) GB0225379D0 (es)
GE (1) GEP20074127B (es)
GT (1) GT200300234A (es)
HK (1) HK1081441A1 (es)
HR (1) HRP20050351A2 (es)
IL (4) IL167799A (es)
IS (1) IS7754A (es)
MA (1) MA27481A1 (es)
MX (1) MXPA05004662A (es)
NL (1) NL1024677C2 (es)
NO (1) NO330496B1 (es)
OA (1) OA12954A (es)
PA (1) PA8587201A1 (es)
PE (1) PE20040553A1 (es)
PL (1) PL376703A1 (es)
RS (1) RS20050333A (es)
TN (1) TNSN05122A1 (es)
TW (2) TW200633699A (es)
UA (1) UA81437C2 (es)
UY (1) UY28043A1 (es)
WO (1) WO2004039367A1 (es)
ZA (1) ZA200502305B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0225379D0 (en) * 2002-10-31 2002-12-11 Pfizer Ltd Therapeutic proline derivatives
US20050043345A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
WO2005097741A1 (en) * 2004-04-05 2005-10-20 Pfizer Limited Process for the recrystallisation of proline derivates
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
JP5138589B2 (ja) * 2006-06-06 2013-02-06 浜松ホトニクス株式会社 神経因性疼痛を抑制するピロリジン類縁体及びその製造方法
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
MX2015017864A (es) 2013-06-26 2016-04-15 Zhejiang Jiuzhou Pharm Co Ltd Metodo de preparacion de derivados de acido pirrolidina-2-carboxil ico.
WO2015003723A1 (en) * 2013-07-12 2015-01-15 Københavns Universitet Substituted 4-proline derivatives as iglur antagonists
CN104418785A (zh) * 2013-09-05 2015-03-18 浙江九洲药业股份有限公司 一种药物中间体的制备方法
CN104829513B (zh) * 2014-02-11 2019-02-19 浙江九洲药业股份有限公司 一种2-羧基-4-甲氧基甲基吡咯烷衍生物的制备方法
CN104844495A (zh) * 2015-06-05 2015-08-19 武汉理工大学 一种(2s,4s)-4-苯硫基-l-脯氨酸盐酸盐的合成方法
WO2020120606A1 (en) * 2018-12-12 2020-06-18 Esteve Pharmaceuticals, S.A. New pyrrolidine-2-carboxylic acid derivatives for treating pain and pain related conditions
TW202026281A (zh) * 2018-12-12 2020-07-16 西班牙商艾斯提夫製藥股份有限公司 用於治療疼痛和疼痛相關病症之新吡咯啶–2– 甲酸衍生物
EP3904339A1 (en) * 2020-04-28 2021-11-03 Esteve Pharmaceuticals, S.A. Alkylaminoproline derivatives as alfa-2-delta-1 blockers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316906A (en) * 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
CA1144930A (en) * 1978-08-11 1983-04-19 Miguel A. Ondetti Mercaptoacyl derivatives of substituted prolines
US4311705A (en) * 1980-10-06 1982-01-19 E. R. Squibb & Sons, Inc. Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines
ZA817601B (en) * 1980-11-24 1982-10-27 Squibb & Sons Inc Carboxyalkyl amino acid derivatives of various substituted prolines
JPH07504155A (ja) * 1991-04-19 1995-05-11 シオス・ノヴァ・インコーポレイテット ブラジキニンアンタゴニストペプチド
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US6156726A (en) * 1996-08-02 2000-12-05 Elan Pharmaceuticals, Inc. Voltage-gated calcium channel antagonist and method
JP3196106B2 (ja) * 1997-03-27 2001-08-06 参天製薬株式会社 ロイコトリエンａ４ヒドロラーゼ阻害剤
JP2002516312A (ja) * 1998-05-26 2002-06-04 ワーナー−ランバート・カンパニー カルシウムチャンネルのα２δサブユニットに対する親和性を有する立体配座的に制約されたアミノ酸化合物
CO5300399A1 (es) * 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
GB0225379D0 (en) * 2002-10-31 2002-12-11 Pfizer Ltd Therapeutic proline derivatives

Also Published As

Publication number Publication date
GB0225379D0 (en) 2002-12-11
ATE468116T1 (de) 2010-06-15
RS20050333A (en) 2007-06-04
NL1024677C2 (nl) 2005-07-04
UY28043A1 (es) 2004-05-31
TW200416030A (en) 2004-09-01
CN100418525C (zh) 2008-09-17
EA009767B1 (ru) 2008-04-28
IL201966A (en) 2011-06-30
KR20070046213A (ko) 2007-05-02
WO2004039367A1 (en) 2004-05-13
OA12954A (en) 2006-10-13
TNSN05122A1 (fr) 2007-05-14
JP2006516115A (ja) 2006-06-22
MXPA05004662A (es) 2005-06-08
CA2499698A1 (en) 2004-05-13
AU2003269411A1 (en) 2004-05-25
EP1558246B1 (en) 2010-05-19
KR20050065646A (ko) 2005-06-29
PL376703A1 (pl) 2006-01-09
ES2343624T3 (es) 2010-08-05
BR0315839A (pt) 2005-09-27
HK1081441A1 (en) 2006-05-19
HRP20050351A2 (en) 2005-10-31
NL1024677A1 (nl) 2004-05-06
JP2006328078A (ja) 2006-12-07
ZA200502305B (en) 2006-11-29
IL201967A (en) 2011-06-30
EA200500581A1 (ru) 2005-12-29
CR7802A (es) 2007-10-23
NO20051407D0 (no) 2005-03-17
UA81437C2 (en) 2008-01-10
CA2499698C (en) 2009-01-20
JP3940416B2 (ja) 2007-07-04
EP1558246A1 (en) 2005-08-03
IS7754A (is) 2005-03-17
TW200633699A (en) 2006-10-01
IL167799A (en) 2011-03-31
GT200300234A (es) 2004-06-23
KR100750782B1 (ko) 2007-08-20
IL201965A (en) 2011-03-31
DK1558246T3 (da) 2010-08-09
GEP20074127B (en) 2007-06-11
AU2003269411B2 (en) 2009-06-18
PA8587201A1 (es) 2004-05-26
PE20040553A1 (es) 2004-08-28
DE60332646D1 (de) 2010-07-01
CN1711081A (zh) 2005-12-21
JP4555263B2 (ja) 2010-09-29
AP2005003295A0 (en) 2005-06-30
MA27481A1 (fr) 2005-08-01
NO20051407L (no) 2005-07-26
CO5550430A2 (es) 2005-08-31
NO330496B1 (no) 2011-05-02
ECSP055769A (es) 2005-08-11

Similar Documents

Publication Publication Date Title
CR7802A (es) Derivados de prolina que presentan afinidad por la subunidad alfa-2-delta del canal de calcio
UY27740A1 (es) Nuevos compuestos
CU23112A3 (es) AMINOáCIDOS BICICLICOS COMO AGENTES FARMACéUTICOS
ECSP066299A (es) Polipéptidos cristalinos del receptor 2 del factor de necrosis de tumor
UY26782A1 (es) Derivados del benzotiazol
ECSP088405A (es) Nuevos derivados de pirimidina y su uso en terapia, así como el uso de derivados de pirimidina en la fabricación de un medicamento para la prevención y/o tratamiento de la enfermedad de alzheimer
CO4810373A1 (es) Compuestos azapoliciclicos condensados con arilo
ECSP088499A (es) Nuevos compuestos de 2-amino-imidazol-4-ona y su uso en la fabricación de un medicamento para uso en el tratamiento de alteración cognitiva, enfermedad de alzheimer, neurodegeneración y demencia
ECSP034732A (es) Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias
AR062536A1 (es) Acilanilidas sustituidas y composicion farmaceutica
CR9954A (es) Derivados de pirazina
AR005458A1 (es) 2-oxo-y 2-tio-1,2-dihidroquinolinil-oxazolidinonas, procedimiento para su produccion, el uso de las mismas para la produccion de un medicamento ymedicamentos que los contienen
AR002289A1 (es) Derivados de acetamida, procedimiento para prepararlos, las composiciones farmaceuticas que los contienen y las aplicaciones de dichos compuestos comoansioliticos y en el tratamiento de enfermedades inmuno-inflamatorias.
PA8587101A1 (es) Nuevos derivados de dihidropirimido [4,5-d] pirimidinona sustituida por amiino, fabricacion y uso de los mismos como agentes farmaceuticos
UY27427A1 (es) Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
UY29818A1 (es) Nuevos compuestos de azetidina, composiciones farmaceuticas que los contienen, procesos de preparacion y sus usos terapeuticos
CY1106645T1 (el) Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος
ECSP034518A (es) Nuevos retinoides para el tratamiento de enfisema
DK1751097T3 (da) Substituerede N-aryl-benzamider og relaterede sammensætninger til behandling af amyloid-sygdomme og synukleinopatier
UY27700A1 (es) Compuestos oxo - azabiclícos.
UY29823A1 (es) Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones
AR066455A2 (es) Uso de compuestos n-metil-n-[(1r)-1-fenil-2-(3r)-3-hidroxipirrolidin -1-il-=-etil]-2,2-difenilacetamida para producir un medicamento para el tratamiento de emfermedades intestinales no inflamatorias
UY28377A1 (es) Agentes terapeuticos
ES2253378T3 (es) Extractos de espermatofitos con actividad antineoplasica.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal